Study on safety monitoring of rivaroxaban by prothrombin time
10.13602/j.cnki.jcls.2019.09.06
- VernacularTitle:用凝血酶原时间监测利伐沙班安全性
- Author:
Rui MA
1
;
Jing REN
1
;
Zhexiang WANG
2
;
Jianlong MEN
1
Author Information
1. Precision Medicine Center, Tianjin Medical University General Hospital
2. School of Medical Laboratory, Tianjin Medical University
- Publication Type:Journal Article
- Keywords:
prothrombin time;
rivaroxaban;
bleeding
- From:
Chinese Journal of Clinical Laboratory Science
2019;37(9):666-670
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety of rivaroxaban by detecting prothrombin time (PT).
Methods:105 patients with thrombosis from May 2018 to February 2019 in Tianjin Medical University General Hospital were selected and followed up. 23 patients with hemorrhage were in the bleeding group and 82 others were in the non-bleeding group. PT was detected by IL ACL TOP 700 blood coagulation instrument and its supporting reagents. Data were expressed as M(P 25 ，P 75 ). Mann-Whitney U test was used for data comparison between the bleeding and non-bleeding groups. Kruskal-Wallis H test was used for age data comparison among multiple groups. The diagnostic performance of PT was evaluated by a receiver operating characteristic curve (ROC).
Results::In the bleeding group, PT changed significantly between before and after treatment of rivaroxaban. On the 1st and 3rd days after treatment, PT peak was significantly higher than the day′s trough level, and on the 3rd day, both the peak value and the trough value were all significantly higher than the levels on the 1st day. There was no significant difference in peak PT between the patients in the non-bleeding group and the bleeding group on the 1st day (P＞0.05), while the trough PT level in the bleeding group was significantly higher than that in the non-bleeding group (P＜0.001). On the 3rd day, the levels of peak and trough PT in the bleeding group were significantly higher than those in non-bleeding (P＜0.001). The diagnostic performance of the trough PT predicting bleeding risk on the day 1 and 3 after treatment was superior to the peak PT level, while the effects of the trough PT predicted on the 1st was similar to the 3rd days. In terms of assessing the risk of bleeding, the trough PT level should be superior to the peak PT, and the 3rd day should be better than the 1st day.
Conclusion:PT could effectively evaluate the bleeding risk of rivaroxaban after sufficient performance verification, and provide a reliable basis for clinical rational use for drug.
